Portuguese cannabis company focused on high quality EU-GACP flower production, EU-GMP processing/manufacturing & branded medical products seeks equity financing to complete build out of purpose-designed 28,000 ft.² EU-GMP production facility
Cannabis pre-licenses granted by INFARMED I.P
Seeking €12 million strategic equity partner
A Portuguese medical cannabis company has a long-term strategy to grow, extract and manufacture EU-GMP certified medical cannabis products
Company is currently focused on production of medical, premium grade cannabis oil, extracts and isolates and potentially development of its own genetics. In addition, Company will provide tolling services to convert GACP flower into EU-GMP complaint flower for the EU market.
Secured a pre-approved, purpose-designed 28,000 ft.² building on a 1.3 acre of land where the EU-GMP compliant production facility is being built
Construction process is successfully ongoing and is expected to be completed in Q3 2023
Experienced, industry-leading international team with deep expertise navigating global medical cannabis markets
In discussion with multiple high-volume, offtake contracts with strong distribution companies in Germany
Company’s goal is become a fully vertically integrated pharmaceutical grade medical cannabis production company
Unique opportunity to invest in the high-growth, medicinal cannabis industry in Europe via one of the few licensed medicinal cannabis extraction facilities in Portugal
Seeking a strategic partner in order to leverage mutual synergies and strengthen the Company’s market position via the completion of the build out of a purpose-designed 28,000 ft.² EU-GMP production facility and its operations to produce premium products tackling oncology and neurology issues.